Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,926,742 papers from all fields of science
Search
Sign In
Create Free Account
idelalisib 150 MG Oral Tablet [Zydelig]
Known as:
IDELALISIB 150 mg ORAL TABLET, FILM COATED [Zydelig]
, Zydelig 150 MG Oral Tablet
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
14 relations
Croscarmellose Sodium
Magnesium stearate
Oral Tablet
Polyethylene Glycols
Expand
Broader (1)
idelalisib Oral Tablet [Zydelig]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Patient Co-Morbidity Profile Should Drive PI3K Inhibitor Selection for Relapsed Follicular Lymphoma
F. Awan
,
R. Chan
,
+6 authors
A. Gopal
Blood
2018
Corpus ID: 201179321
Background: Idelalisib (Zydelig®, IDELA), an oral agent, and copanlisib (Aliqopa®, COPA), an intravenous agent, are the only B…
Expand
2016
2016
Idelasilib (▼Zydelig®): se ha revaluado su balance beneficio-riesgo a nivel europeo
M. Sanz
2016
Corpus ID: 184919864
2016
2016
Idelalisib (▼ Zydelig®): restricciones temporales de uso para prevenir infecciones graves mientras se realiza la revaluación europea del balance beneficio-riesgo
A. E. D. M. Y. P. Sanitarios
2016
Corpus ID: 164393233
2016
2016
Idelalisib (▼ Zydelig®): leucemia linfocítica crónica y linfoma folicular
S. Cuéllar
2016
Corpus ID: 79041805
Review
2015
Review
2015
Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin’s lymphoma
G. Keating
Targeted Oncology
2015
Corpus ID: 31323844
Idelalisib (Zydelig®) is a first-in-class, orally administered, phosphatidylinositol 3-kinase-δ inhibitor that was recently…
Expand
2015
2015
Development of Drugs Targeting the PI3K Signalling Pathway in Leukaemias and Lymphomas
A. Arcaro
2015
Corpus ID: 38444234
The phosphoinositide 3-kinase (PI3K) family of signalling enzymes play a key role in the transduction of signals from activated…
Expand
Highly Cited
2014
Highly Cited
2014
Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and…
J. Sharman
,
S. Coutre
,
+18 authors
S. Stilgenbauer
2014
Corpus ID: 79314797
BACKGROUND: There is high unmet need in frail pts with relapsed CLL, particularly in those characterized by adverse prognostic…
Expand
Review
2014
Review
2014
Idelalisib: First Global Approval
A. Markham
Drugs
2014
Corpus ID: 207488424
Idelalisib (Zydelig®) is a highly specific small-molecule phosphatidylinositol-3-kinase (PI3Kδ) inhibitor that has been developed…
Expand
2014
2014
Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic…
R. Furman
,
S. Vos
,
+11 authors
S. Coutre
2014
Corpus ID: 74038879
Introduction: PI3Kδ signaling is critical for the proliferation, survival and homing/tissue retention of malignant B cells…
Expand
2014
2014
Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia
E. Rothschedl
,
R. Joppi
,
C. Poggiani
2014
Corpus ID: 69127406
Idelalisib (Zydelig®) is an inhibitor of the B-cell receptor signaling pathway; it is indicated in combination with rituximab in…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE